753 An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors

• Costantine Albany,
• Andrea Pirzkall,
• Michael Chisamore,
• Jennifer Visich,
• Elizabeth I Buchbinder,
• Xiaohan Liu,
• David R Spigel,
• Kelly D Moynihan,
• Christopher DelNagro,
• Matt Axt,
• Mark Sayles

Affiliations

Costantine Albany

2Horizon Oncology and Research Center, Lafayette, IN, USA

Andrea Pirzkall

Aff3 0000 0004 0534 4718grid.418158.1Genentech, Inc. South San Francisco CA USA

Michael Chisamore

4Merck and Co., Inc., Rahway, NJ, USA

Jennifer Visich

8Genentech Research & Early Development, South San Francisco, California, USA

Elizabeth I Buchbinder

Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA

Xiaohan Liu

Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China

David R Spigel

Department of Thoracic Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA

Kelly D Moynihan

4Asher Biotherapeutics, Inc., South San Francisco, CA, USA

Christopher DelNagro

4Asher Biotherapeutics, Inc., South San Francisco, CA, USA

Matt Axt

4Asher Biotherapeutics, Inc., South San Francisco, CA, USA

Mark Sayles

4Asher Biotherapeutics, Inc., South San Francisco, CA, USA